© Rosalind Scientific LLC 2018-2022
© Rosalind Scientific LLC, 2018-2022
New Drug Hunter content, featured events and job postings straight to your inbox. Trusted by >3,500 drug hunters worldwide, unsubscribe anytime.
<< Back to March
oral PRMT5 inh. for treating cancers
projected human dose of 15 mg QD w/ 6 HBD
SBDD from SAM cofactor
J. Med. Chem., Mar. 23, 2021
Merck & Co, Boston, MA
The Merck protein arginine methyltransferase 5 (PRMT5) inhibitor (“compound 72”) is a SAM cofactor-mimetic with a novel 5,5-fused carbon-based bicyclic scaffold. PRMT5 is an actively pursued epigenetic target for…
Ask your company or librarian about a Drug Hunter membership to to see all summaries and get access to even more helpful information.